The effect of variation of fatty substances found in the blood on patients with type 2 diabetes
| ISRCTN | ISRCTN27314990 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN27314990 |
| IRAS number | 154259 |
| Secondary identifying numbers | IRAS 154259 |
- Submission date
- 19/10/2020
- Registration date
- 09/11/2020
- Last edited
- 09/11/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
High blood sugar and fat content are well-recognised risk factors for causing the formation of obstructive plaques in arteries which lead to cardiovascular disease, for example heart attacks. From earlier studies, we know that after eating, high sugar and fat content in the blood seems to have an association with cardiovascular risk in both healthy persons and individuals with type 2 diabetes. This study aims to examine the effect on the body of variation of fat levels in the blood compared to constant fat levels, during a constant high sugar state.
Who can participate?
This study is open to individuals with type 2 diabetes and non-diabetic individuals between the ages of 30 - 65 years with a body mass index between 27 - 40 kg/m² (overweight or obese).
What does the study involve?
This study includes one screening visit and two procedural visits during which participants will have sugar infused into their blood. Blood will be drawn at various time points during the procedure for analysis. Participants will be closely monitored by trained medical and nursing staff throughout the procedure. There will be one week break between visit 2 and visit 3 to prevent the carried over effects of infusions. We expect individual participants would be in the study for 3-4 weeks in total.
What are the possible benefits and risks of participating?
Benefits: No immediate benefits, however, the knowledge gained in the study will help the management of diabetes in the future.
Risks: Potential for a reaction to the fatty substance given by the drip and discomfort from the cannula (plastic needle). A fully advanced life support trained research doctor will be present at all times to manage any emergency situation that arises however this is a rare occurrence. All the potential risks will be fully disclosed and discussed with potential participants at screening before he/she consents to take part in the study.
Where is the study run from?
University of Hull (UK)
When is the study starting and how long is it expected to run for?
June 2014 to October 2021
Who is funding the study?
University of Hull (UK)
Who is the main contact?
Prof. Thozhukat Sathyapalan, thozhukat.sathyapalan@hey.nhs.uk
Contact information
Scientific
Academic Diabetes, Endocrinology and Metabolism
Hull Royal infirmary
Brocklehurst Building
Anlaby Road
Hull
HU3 2RW
United Kingdom
 ORCID ID |
0000-0003-3544-2231 |
|---|---|
| Phone | +44 (0)1482675312 |
| thozhukat.sathyapalan@hey.nhs.uk |
Study information
| Study design | Pilot cross-sectional non-randomised non-CTIMP |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Diagnostic |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet. |
| Scientific title | Effect of acute fluctuations of hyperlipidaemia on insulin resistance and cardiovascular risk in patients with type 2 diabetes |
| Study objectives | Fluctuation in triglyceride levels confers risk of oxidative stress, beta-cell function and platelet function that is in addition to that predicted by the plasma mean triglyceride value alone. |
| Ethics approval(s) | Approved 03/12/2014, NRES Committee Yorkshire & The Humber - South Yorkshire (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)207 104 8079; southyorks.rec@hra.nhs.uk), ref: 14/YH/1169 |
| Health condition(s) or problem(s) studied | Assessing risk of fluctuating lipid levels compared to constant hyperlipidaemia during constant hyperglycaemic state on endothelial function and oxidative stress parameters in type 2 diabetes |
| Intervention | This study includes one screening visit and two procedural visits. There will be a one week break between visit 2 and visit 3. We expect he or she would be in the study for 3-4 weeks in total. All the participants have a screening assessment to ensure their eligibility for the study and will be required to complete a consent form. The screening includes medical history (including pre-existing conditions and concomitant medications), physical examinations (measurement of height, weight, hip and waist circumference, and resting blood pressure) and blood tests. In women, a pregnancy test will be done before entering the study. Female participants will be asked to use a barrier method for contraception if required during the test. For visit 2, participants will be required to fast for 12 h, not take their antiplatelet medication (e.g. aspirin) for 72 h before the test, not take their metformin and blood pressure medication on the evening before and the morning of the visit. Participants will also be requested to stop their lipid lowering medication i.e statins 4 weeks before entering the study. A cannula (plastic needle) will be inserted in both forearms. A hyperglycaemic state will be maintained using 20% Dextrose Infusion followed by continuous 20% IV Lipid infusion 90 ml/h and unfractionated heparin. Another cannula will be inserted in the back of the hand and subjected to controlled heat to allow for blood sample collection. A blood sample will be collected at various time points throughout the test. A similar procedure will be repeated on visit 3 (1 week after visit 2). A hyperglycaemic state will be maintained using 20% Dextrose Infusion followed by intermittent 20% IV Lipid infusion 90 ml/h and unfractionated heparin for 2 hours followed by Normal Saline 45 ml/h for 2 h before re-starting 20% IV Lipid infusion 90 ml/h and unfractionated heparin. Blood glucose will be checked before sending participants home. Participants should expect to stay in the centre for approximately 8 h. The expenses for travel and parking fees will be reimbursed. Because of the inconvenience of having to spend 8 h in the diabetes centre for the procedure, we will reimburse participants £50 per procedure. However, participants would not be eligible for the reimbursement if they are on state benefit because it might invalidate their benefits. |
| Intervention type | Other |
| Primary outcome measure | 1. Beta cell function assessed by insulin measurements taken at fasting and every 10 min from T-30 to T0 and T340 to T360, and hourly during the whole procedure 2. Oxidative stress markers measured using blood samples drawn during visit 2 and 3 before, at the end of 2 h, 4 h and 6 h of the fatty substance infusion and will be centrifuged followed by analysis using the flow cytometer |
| Secondary outcome measures | Platelet activation/inhibition measured using blood samples drawn during visit 2 and 3 before, at the end of 2 h, 4 h and 6 h of the lipid infusion and will be centrifuged followed by analysis using the flow cytometer |
| Overall study start date | 01/06/2014 |
| Completion date | 15/10/2021 |
Eligibility
| Participant type(s) | All |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 32 |
| Key inclusion criteria | Diabetes arm: 1. Aged 30 - 65 years 2. BMI 27 - 40 kg/m² 3. History of T2DM on diet with or without metformin Control arm 1. Aged 30 - 65 years 2. BMI 27 - 40 kg/m² |
| Key exclusion criteria | Diabetes arm: 1. Current smoking 2. Pregnancy/breastfeeding/trying to conceive 3. Participants on anti-diabetes medications except metformin 4. Participants on beta blocker/ thiazide diuretics 5. History of chronic kidney disease stage 3, ALT >3x upper limit of normal and active thyroid disease 6. History of recent cardiovascular event in last 12 weeks 7. History of coagulation disorders 8. History of bronchial asthma 9. History of allergy to insulin, soy oil, purified egg (intralipid) 10. History of taking lipid lowering agents within last 2 weeks 11. Unwilling to be informed to their GP about their participation Control arm: 1. Current smoking 2. Pregnancy/breastfeeding/trying to conceive 3. History of chronic kidney disease stage 3, ALT >3x upper limit of normal and active thyroid disease 4. History of recent cardiovascular event in last 12 weeks 5. History of coagulation disorders 6. History of bronchial asthma 7. History of diabetes mellitus 8. Participants on beta-blockers or thiazide diuretics 9. History of allergy to insulin, soy oil, purified egg (intralipid) 10. History of taking lipid lowering agents within last 4 weeks 11. Unwilling to be informed to their GP about their participation |
| Date of first enrolment | 20/12/2020 |
| Date of final enrolment | 20/06/2021 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Brocklehurst Building
220-236 Anlaby Road
Hull
HU3 2RW
United Kingdom
Sponsor information
Hospital/treatment centre
Office 13, 2nd Floor Daisy Building
Castle Hill Hospital
Cottingham
HU16 5JQ
England
United Kingdom
| Phone | +44 (0)1482461903 |
|---|---|
| james.illingworth@hey.nhs.uk | |
| Website | http://www.hey.nhs.uk/ |
"ROR" |
https://ror.org/01b11x021 |
Funders
Funder type
University/education
Private sector organisation / Universities (academic only)
- Alternative name(s)
- HU
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 20/09/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Hull and East Yorkshire R & D department will monitor all data collected including safety data throughout the course of the study. The data stored will only have the participant’s study number and initials on it. Data will be collected in participant’s case notes and a case report form (CRF) designed specifically for the study in line with the sponsor’s guidelines and Good Clinical Practice. Data will be collected by the study team. This will include research nurses and medical practitioners. Data will be anonymized and will only be identified by the participant identification number. Data will be collected and retained in accordance with the Data Protection Act 1998. Data will include anthropometric measurements, laboratory investigations which include full blood count , urea, creatinine & electrolytes, liver function test, thyroid function test, HbA1C, creatinine kinase, total cholesterol, triglycerides, LDL and HDL, Insulin and oxidative stress markers (endothelial microparticles) will be examined by local laboratory protocol. Data will can be made available from July 2021 and will be available for 5 years. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol file | version v2 | 24/06/2014 | 09/11/2020 | No | No |
| HRA research summary | 28/06/2023 | No | No |
Additional files
- ISRCTN27314990_PROTOCOL_v2_24Jun2014.doc
- uploaded 09/11/2020
Editorial Notes
09/11/2020: Uploaded protocol (not peer reviewed) Version 2, 24 June 2014.
22/10/2020: Trial’s existence confirmed by NRES Committee Yorkshire & The Humber - South Yorkshire
